$1.93
7.66% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US71880W2044
Symbol
PHIO
Sector
Industry

Phio Pharmaceuticals Corp. Stock price

$1.93
-0.71 26.76% 1M
-4.27 68.89% 6M
-4.91 71.78% YTD
-4.83 71.45% 1Y
-120.11 98.42% 3Y
-868.87 99.78% 5Y
-944,458.07 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.16 7.66%
ISIN
US71880W2044
Symbol
PHIO
Sector
Industry

Key metrics

Market capitalization $3.34m
Enterprise Value $-2.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.25
P/B ratio (TTM) P/B ratio 0.37
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-7.49m
Free Cash Flow (TTM) Free Cash Flow $-8.11m
Cash position $5.39m
EPS (TTM) EPS $-13.94
Short interest 6.00%
Show more

Is Phio Pharmaceuticals Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Phio Pharmaceuticals Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:

Buy
100%

Financial data from Phio Pharmaceuticals Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.08 0.08
58% 58%
-
-0.08 -0.08
58% 58%
-
- Selling and Administrative Expenses 3.67 3.67
15% 15%
-
- Research and Development Expense 3.67 3.67
47% 47%
-
-7.41 -7.41
35% 35%
-
- Depreciation and Amortization 0.08 0.08
58% 58%
-
EBIT (Operating Income) EBIT -7.49 -7.49
36% 36%
-
Net Profit -7.42 -7.42
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Phio Pharmaceuticals Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Head office United States
CEO Robert Bitterman
Employees 9
Founded 2011
Website www.phiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today